New drug combo aims to stop breast Cancer's comeback
Disease control
Recruiting now
This study is testing whether adding the drug ribociclib to standard hormone therapy can better prevent breast cancer from returning in patients who have already had a local recurrence surgically removed. The trial will enroll 200 adults with hormone-sensitive, HER2-negative brea…
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC